| Literature DB >> 25313865 |
Sang Youb Han1, Jae Won Hong1, Jung Hyun Noh1, Dong-Jun Kim1.
Abstract
BACKGROUND: Sodium intake and albuminuria have important roles in blood pressure and renal progression. Although their relationship has been reported, the results have not been consistent and all studies have examined small populations.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25313865 PMCID: PMC4196757 DOI: 10.1371/journal.pone.0109073
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Age, sex, and age- and sex-adjusted demographic and clinical characteristics of the Korean population, age 19 years and older, in the 2011 KNHANES according to albuminuria.
| NA | mA | MA |
| |
| Number (weighted) | 4793 | 328 | 66 | |
| Age (years) | 50.4±0.2 | 61.4±0.9 | 63.7±2.0 | <0.001 |
| Female (%) | 55.0 | 55.0 | 51.5 | 0.492 |
| Current smoking (%) | 20.8±0.5 | 24.1±2.0 | 25.2±4.5 | 0.181 |
| Heavy alcohol drinking (%) | 7.2±0.4 | 8.2±1.4 | 7.1±3.1 | 0.768 |
| Regular exercise (%) | 13.1±0.5 | 9.5±1.9 | 16.7±4.1 | 0.116 |
| Waist circumference (cm) | 81.6±0.1 | 83.9±0.5 | 84.2±1.2 | <0.001 |
| BMI (kg/m2) | 23.7±0.1 | 24.3±0.2 | 24.2±0.4 | 0.003 |
| Obesity (%) | 32.3±0.7 | 39.5±2.6 | 35.9±5.8 | 0.028 |
| Systolic BP (mmHg) | 118.8±0.2 | 126.6±0.8 | 135.3±1.9 | <0.001 |
| Diastolic BP (mmHg) | 75.6±0.1 | 78.2±0.6 | 78.8±1.2 | <0.001 |
| Anti-hypertensive drugs (%) | 20.2±0.5 | 36.2±2.0 | 46.7±4.5 | <0.001 |
| Hypertension (%) | 30.7±0.6 | 52.2±2.3 | 63.5±5.1 | <0.001 |
| FPG (mg/dL) | 97.0±0.3 | 107.4±1.2 | 127.7±2.7 | <0.001 |
| Diabetes (%) | 9.5±0.4 | 27.1±1.7 | 44.9±3.7 | <0.001 |
| Serum LDL-C (mg/dL) | 114.9±0.8 | 111.2±3.6 | 121.8±8.4 | 0.417 |
| Serum TG (mg/dL) | 132.6±1.5 | 152.5±5.8 | 189.1±12.9 | <0.001 |
| Anti-lipid drug (%) | 6.5±0.4 | 9.4±1.4 | 10.3±3.0 | 0.068 |
| Serum creatinine (mg/dL) | 0.8±0.1 | 0.9±0.1 | 1.1±0.1 | <0.001 |
| eGFR (ml/min/1.73 m2) | 86.8±0.2 | 86.3±0.8 | 75.5±1.8 | <0.001 |
| eGFR<60 ml/min/1.73 m2 (%) | 3.6±0.3 | 9.4±1.1 | 29.8±2.4 | <0.001 |
| ACR (mg/g) | 4.3±2.0 | 84.3±7.6 | 1025.4±16.7 | <0.001 |
| Urine Na+ (mmol/L) | 124.9±0.7 | 125.7±2.9 | 112.6±6.3 | 0.148 |
| Urine Cr (mmol/L) | 13.2±0.1 | 12.1±0.4 | 11.1±0.8 | 0.002 |
| U [Na+]/[Cr] (mmol/mmol) | 12.7±0.1 | 14.7±0.5 | 15.9±1.0 | <0.001 |
| 24-h urinary sodium (mg/day) | 4383±40 | 5080±156 | 5440±345 | <0.001 |
Data are expressed as means with SEM. Abbreviations: albuminuria, microalbuminuria or macroalbuminuria; NA, normoalbuminuria; mA, microalbuminuria; MA, macroalbuminuira; BMI, body mass index; obesity, BMI ≥25 kg/m2 or more; BP, blood pressure; hypertension, systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or use of antihypertensive medications irrespective of BP; FPG, fasting plasma glucose; diabetes, fasting plasma glucose ≥7.0 mmol/L or current anti-diabetes medication or a previous diagnosis of diabetes by a physician; LDL-C, low density lipoprotein-cholesterol; TG, triglyceride; eGFR, estimated glomerular filtration rate; ACR, albumin-creatinine ratio.
Age, sex, and age- and sex-adjusted demographic and clinical characteristics of the Korean population, age 19 years and older, in the 2011 KNHANES based on the estimated 24-h urinary sodium excretion.
| Quartile 1(149–2360 mg/day) | Quartile 2(2361–3765 mg/day) | Quartile 3(3766–5780 mg/day) | Quartile 4(5781–31021 mg/day) |
| |
| Number (weight) | 1282 | 1300 | 1304 | 1301 | |
| Age (years) | 45.2±0.4 | 48.4±0.4 | 53.5±0.4 | 58.0±0.4 | <0.001 |
| Female (%) | 47.5 | 51.7 | 57.0 | 64.3 | <0.001 |
| Waist circumference (cm) | 80.0±0.3 | 81.5±0.3 | 82.1±0.3 | 83.5±0.3 | <0.001 |
| BMI (kg/m2) | 23.2±0.1 | 24.7±0.1 | 23.8±0.1 | 24.3±0.1 | <0.001 |
| Obesity (%) | 28.1±1.3 | 33.1±1.3 | 32.5±1.3 | 37.6±1.3 | 0.028 |
| Systolic BP (mmHg) | 117.3±0.4 | 118.3±0.4 | 119.5±0.4 | 123.0±0.4 | <0.001 |
| Diastolic BP (mmHg) | 74.6±0.3 | 75.5±0.3 | 76.0±0.3 | 77.3±0.3 | <0.001 |
| Anti-hypertensive drugs (%) | 26.3±1.0 | 21.4±1.0 | 18.4±1.0 | 20.3±1.0 | <0.001 |
| Hypertension (%) | 33.5±1.2 | 31.2±1.2 | 30.8±1.2 | 34.4±1.2 | 0.080 |
| FPG (mg/dL) | 99.0±0.6 | 97.5±0.6 | 97.9±0.6 | 97.7±0.6 | 0.290 |
| Diabetes (%) | 11.7±0.9 | 9.6±0.8 | 11.2±0.8 | 11.6±0.9 | 0.259 |
| Serum LDL-C (mg/dL) | 116.0±1.5 | 114.8±1.6 | 115.5±1.6 | 112.5±1.7 | 0.445 |
| Serum TG (mg/dL) | 126.4±3.0 | 127.7±2.9 | 139.1±2.9 | 144.9±3.0 | <0.001 |
| Anti-lipid drug (%) | 8.1±0.7 | 6.1±0.7 | 6.7±0.7 | 6.0±0.7 | 0.118 |
| eGFR (ml/min/1.73 m2) | 83.7±0.4 | 85.5±0.4 | 86.7±0.4 | 90.7±0.4 | <0.001 |
| eGFR<60 ml/min/1.73 m2(%) | 3.6±0.3 | 9.4±1.1 | 29.8±2.4 | 144.9±3.0 | 0.122 |
| Urine Na+ (mmol/L) | 82.2±1.3 | 119.6±1.2 | 140.0±1.2 | 156.8±1.3 | <0.001 |
| Urine Cr (mmol/L) | 20.0±0.1 | 13.9±0.1 | 10.8±0.1 | 7.7±0.1 | <0.001 |
| U [Na+]/[Cr] (mmol/mmol) | 5.0±0.1 | 8.9±0.1 | 13.3±0.1 | 24.1±0.1 | <0.001 |
Data are expressed as means ± SEM. Abbreviations: BMI, body mass index; obesity, BMI ≥25 kg/m2 or more; BP, blood pressure; hypertension, systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or use of antihypertensive medications irrespective of BP; FPG, fasting plasma glucose; diabetes, fasting plasma glucose ≥7.0 mmol/L or current anti-diabetes medication or a previous diagnosis of diabetes by a physician; LDL-C, low density lipoprotein-cholesterol; TG, triglyceride; eGFR, estimated glomerular filtration rate.
Prevalence of albuminuria according to the estimated 24-h urinary Na excretion.
| Estimated 24-h urinary Na excretion (mg/day) |
|
| ||||
| Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | |||
| Model 1 | 5.3 | 5.7 | 7.5 | 11.8 | <0.001 | <0.001 |
| Model 2 | 7.0±0.7 | 6.5±0.7 | 6.9±0.7 | 9.9±0.7 | 0.004 | 0.003 |
| Model 3 | 6.8±0.7 | 6.8±0.7 | 7.0±0.7 | 9.8±0.7 | 0.009 | 0.005 |
Model 1, no adjustments;
Model 2, adjusted for age and sex;
Model 3, adjusted for diabetes, hypertension, obesity, and the variables in Model 2.
Odds ratio for albuminuria in each quartile of estimated 24-h urine sodium with the first quartile as a control.
| Model 1 | Model 2 | Model 3 | ||||
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| |
| 0.001 | 0.005 | 0.005 | ||||
| 1st quartile | - | - | - | - | - | - |
| 2nd quartile | 0.98 (0.70–1.38) | 0.917 | 1.05 (0.74–1.50) | 0.771 | 1.00 (0.68–1.46) | 0.992 |
| 3rd quartile | 1.12 (0.81–1.55) | 0.508 | 1.14 (0.81–1.59) | 0.454 | 1.12 (0.78–1.61) | 0.528 |
| 4th quartile | 1.63 (1.20–1.22) | 0.002 | 1.61 (1.17–2.21) | 0.003 | 1.63 (1.16–2.29) | 0.005 |
Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex, diabetes, hypertension, and obesity.
Model 3: Model 2 after excluding eGFR <60 ml/min/1.73 m2 (n = 4964).